Someone has to say the simple truth. As an overextended shareholder whose average price is way above current prices I am sad to have to read the corporate update and the current PR and state the obvious. WHEN we get efficacy data I will be as excited as anyone, moreso I would guess, since part of my job is seeing cancer patients almost every shift at work